• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes, obesity & metabolism >Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes
【24h】

Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes

机译：沙格列汀联合二甲双胍联合达格列净联合三联疗法在2型糖尿病患者中的疗效和安全性超过52周

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We previously reported that dapagliflozin versus placebo as add-on to saxagliptin plus metformin resulted in greater reductions in glycated haemoglobin (A1C), fasting plasma glucose (FPG) and body weight (BW) after 24 weeks of treatment in patients with type 2 diabetes (T2D). Here we report results after 52 weeks of treatment. Patients stabilized on open-label metformin and saxagliptin 5 mg/day for 8-16 weeks were randomized to placebo or dapagliflozin 10 mg/day plus open-label saxagliptin plus metformin for 52 weeks. Changes from baseline to week 52 were greater with dapagliflozin versus placebo in A1C (-0.74% vs. 0.07%), FPG (-27 vs. 10 mg/dL) and BW (-2.1 vs. -0.4 kg). More patients achieved A1C <7% with dapagliflozin (29.4%) versus placebo (12.6%). Adverse events were similar with dapagliflozin (66%) and placebo (71%), and hypoglycaemia was rare (<= 2%). Genital infections occurred more often with dapagliflozin (6%) than with placebo (1%); frequency of urinary tract infections was similar between the two groups (9% vs. 10%). Triple therapy with dapagliflozin add-on to saxagliptin plus metformin is a durable, effective and well-tolerated intervention for the treatment of T2D.
机译：我们先前曾报道，对于2型糖尿病患者，治疗24周后，沙格列汀加二甲双胍与dapagliflozin相比于安慰剂可导致糖化血红蛋白（A1C），空腹血糖（FPG）和体重（BW）的更大降低（ T2D）。在这里，我们报告治疗52周后的结果。服用开放性二甲双胍和沙格列汀5 mg /天稳定8-16周的患者被随机分组​​接受安慰剂或dapagliflozin 10 mg /天加开放性沙克列汀+二甲双胍52周。在A1C（-0.74％vs. 0.07％），FPG（-27 vs. 10 mg / dL）和BW（-2.1 vs. -0.4 kg）中，达格列净与安慰剂相比，从基线到第52周的变化更大。与安慰剂（12.6％）相比，更多的达格列净（29.4％）患者达到A1C <7％。达格列净（66％）和安慰剂（71％）的不良事件相似，低血糖症很少见（<= 2％）。达格列净（6％）比安慰剂（1％）多发生于生殖器感染。两组之间的尿路感染发生率相似（9％vs. 10％）。沙格列汀加二甲双胍联合达格列净添加三联疗法是治疗T2D的持久，有效且耐受良好的干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号